Henry M. Jackson Foundation for the Advancement of Military Medicine

Advancing Military Medicine

Search Results - prostate+cancer

4 Results Sort By:
DNA Damage Repair Genes in Prostate Cancer - (HJF 557-19)
Prostate cancer patients with DDRG mutations are increasingly considered for targeted cancer therapies. Currently available DDRG mutation tests rely on a rather small number of genes which are not often mutated in African American prostate cancer patients. This invention describes a robust data set on inherited mutations which can be used to develop...
Published: 5/6/2024   |   Updated: 12/1/2023   |   Inventor(s): Gyorgy Petrovics, Shiv Srivastava
Keywords(s): African American, Caucasian, DDRG, Mutation, Precision Therapy, Prostate Cancer
Category(s): Diagnostics
ETV1 Monoclonal Antibodies - (HJF 641-23)
ETV1 is a protein of Erythroblast Transformation Specific (ETS) family of transcription factors. Dysregulation of ETV-1 has been observed in many malignancies including, gastrointestinal stromal (GIS), prostatic tumors, and in triple-negative breast cancer. Researchers at Henry M. Jackson Foundation (HJF) and Uniformed Services University for Health...
Published: 10/17/2024   |   Updated: 4/5/2023   |   Inventor(s): Shyh-Han Tan, Albert Dobi, Shiv Srivastava
Keywords(s): ERG, Monoclonal Antibodies, Prostate Cancer
Category(s): Diagnostics, Research Tool, Therapeutic
Urine-Based Prostate Cancer Diagnostics - (HJF 485-17)
A technology for screening and diagnosing prostate cancer based on urine exosomes is available for licensing from HJF. Applications and Advantages Screening for and diagnosis prostate cancer with superior accuracy than the standard of care. Convenience of using regular urine sample that can be collected at home, as opposed to post-DRE urine sample. RNA...
Published: 10/17/2024   |   Updated: 1/19/2023   |   Inventor(s): Shiv Srivastava, Gyorgy Petrovics, Indu Kohaar
Keywords(s): Diagnostics, Prostate Cancer
Category(s): Diagnostics
Small Molecule Inhibitors of ERG Oncoprotein - (HJF 578-20, HJF 393-15, and HJF 324-13)
HJF scientists have developed a first-in-class family of novel and potent small molecule ERG inhibitors that can be used as targeted therapeutics for malignant diseases with overexpression of ERG oncoproteins. Therapeutic indications may include prostate cancer, leukemia, and colorectal cancer. Applications and Advantages First-in-class small molecule...
Published: 10/17/2024   |   Updated: 3/8/2022   |   Inventor(s): Albert Dobi, Sanjay Malhotra, Mallesh Pandrala, Binil Eldhose
Keywords(s): Cancer, Colorectal Cancer, ERG, Leukemia, Oncogene, Prostate Cancer, Small Molecule, Therapeutics
Category(s): Therapeutic